Product References
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.
Biomolecules
Zirjacks L,Stransky N,Klumpp L,Prause L,Eckert F,Zips D,Schleicher S,Handgretinger R,Huber SM,Ganser K
Published figure using ALDH1A3 polyclonal antibody (Product # PA5-29188) in Western Blot
Thu Oct 21 00:00:00 UTC 2021
ALDH1A3 Segregated Expression and Nucleus-Associated Proteasomal Degradation Are Common Traits of Glioblastoma Stem Cells.
Biomedicines
Fauß J,Sprang B,Leukel P,Sommer C,Nikolova T,Ringel F,Kim EL
PA5-29188 was used in Immunocytochemistry-immunofluorescence to support the association of ALDH1A3 with glioblastoma stem cells and provide evidence for the regulation of ALDH1A3 activities at the level of protein turnover.
Wed Dec 22 00:00:00 UTC 2021
High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.
PloS one
Nozaki Y,Motomura H,Tamori S,Kimura Y,Onaga C,Kanai S,Ishihara Y,Ozaki A,Hara Y,Harada Y,Mano Y,Sato T,Sato K,Sasaki K,Ishiguro H,Ohno S,Akimoto K
PA5-29188 was used in Immunocytochemistry-immunoflourescence to report that PKCλ expression was enriched in basal-like breast cancer, among breast cancer subtypes, and was correlated with ALDH1A3 expression (p = 0.016, χ2-test).
Thu Sep 10 00:00:00 UTC 2020
High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.
PloS one
Nozaki Y,Motomura H,Tamori S,Kimura Y,Onaga C,Kanai S,Ishihara Y,Ozaki A,Hara Y,Harada Y,Mano Y,Sato T,Sato K,Sasaki K,Ishiguro H,Ohno S,Akimoto K
PA5-29188 was used in Immunocytochemistry-immunoflourescence to report that PKCλ expression was enriched in basal-like breast cancer, among breast cancer subtypes, and was correlated with ALDH1A3 expression (p = 0.016, χ2-test).
Thu Sep 10 00:00:00 UTC 2020
High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.
PloS one
Nozaki Y,Motomura H,Tamori S,Kimura Y,Onaga C,Kanai S,Ishihara Y,Ozaki A,Hara Y,Harada Y,Mano Y,Sato T,Sato K,Sasaki K,Ishiguro H,Ohno S,Akimoto K
PA5-29188 was used in Immunocytochemistry-immunoflourescence to report that PKCλ expression was enriched in basal-like breast cancer, among breast cancer subtypes, and was correlated with ALDH1A3 expression (p = 0.016, χ2-test).
Thu Sep 10 00:00:00 UTC 2020
High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.
PloS one
Nozaki Y,Motomura H,Tamori S,Kimura Y,Onaga C,Kanai S,Ishihara Y,Ozaki A,Hara Y,Harada Y,Mano Y,Sato T,Sato K,Sasaki K,Ishiguro H,Ohno S,Akimoto K
PA5-29188 was used in Immunocytochemistry-immunoflourescence to report that PKCλ expression was enriched in basal-like breast cancer, among breast cancer subtypes, and was correlated with ALDH1A3 expression (p = 0.016, χ2-test).
Thu Sep 10 00:00:00 UTC 2020
Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
Breast cancer research : BCR
Bhat K,Sandler K,Duhachek-Muggy S,Alli C,Cheng F,Moatamed NA,Magyar CE,Du L,Li G,McCloskey S,Vlashi E,Pajonk F
PA5-29188 was used in Immunohistochemistry to conclude that physiologically slow-rising serum erythropoietin levels in response to tumor-related or chemotherapy-induced anemia, as opposed to large doses of recombinant erythropoietin, do not increase the pool of breast cancer-initiating cells.
Wed Jan 30 00:00:00 UTC 2019
Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3.
Theranostics
Lu T,Bankhead A,Ljungman M,Neamati N
PA5-29188 was used in Western Blotting to provide a rich, multi-faceted summary of the molecular mechanisms impacted by STAT3 deletion and provide new insight for STAT3's potential as a therapeutic target in ovarian cancer.
Wed Sep 09 00:00:00 UTC 2020